Global TB CAB welcomes introduction of safer drug for most South Africans with rifampicin-resistant TB; Other countries and the World Health Organization must now follow. 19 June 2018 – The Global Tuberculosis Community Advisory Board (Global TB CAB) welcomes the announcement…
FEBRUARY 1, 2018 — The Global Tuberculosis Community Advisory Board (TB CAB) is a group of research- literate treatment activists from around the world who work in an advisory capacity to researchers and product developers conducting trials of new and…
AUGUST 17, 2017 – One of the most critical scientific questions in tuberculosis (TB) today is the optimal combination of new and repurposed drugs for the treatment of extensively drug-resistant, pre-extensively drug-resistant, and hard-to-treat multidrug-resistant TB (XDR–TB, pre–XDR–TB, MDR–TB). Preliminary…